Advanced Medical Equipment & Technology

Cepheid raises FY 2014 revenue guidance; raises low end of prior FY 2014 EPS guidance

Cepheid:Expects FY 2014 total revenue in the range of $461 to $465 million.Expects FY 2014 Net loss in a range from $(0.54) to $(0.52) per share.Expects FY 2014 Non-GAAP net income in the range of $0.11 to $0.13 per share.FY 2014 revenue of $459 million - Thomson Reuters I/B/E/S.

Thursday, 16 Oct 2014 04:04pm EDT

Quidel Corp receives FDA clearance for Lyra Molecular PCR Assay

Quidel Corp:Received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Parainfluenza Assay.Says it is a real-time PCR test for the qualitative detection and identification of human parainfluenza virus (HPIV) infections for virus types 1, 2, or 3 viral RNA...

Wednesday, 15 Oct 2014 02:00pm EDT

Theraclion presents positive trial results

Theraclion SA:Presents positive results from a study published in the International Journal of Hyperthermia.Study was on the early assessment by thyroid function of benign thyroid.Study showed the safety and the effectiveness of echopulse in the treatment of benign hot and cold thyroid nodules by...

Wednesday, 15 Oct 2014 12:00pm EDT

Luminex Corp announces retirement of Patrick Balthrop, President and CEO

Luminex Corp:Says Patrick J. Balthrop, Sr. has retired as President and CEO.Says board has named Nachum Homi Shamir as President and CEO.

Wednesday, 15 Oct 2014 08:50am EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.